What Lessons Should Pharmaceutical Manufacturers Take Away from Operation Warp Speed?

  • Offering an overview of the public-private partnership that facilitated and accelerated the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics
  • During the pandemic our industry faced crisis and achieved the seemingly impossible. What drives an extraordinary performance?
  • Building stronger bonds of communication, collaboration, and coordination between industry partners and regulators to serve patients better
  • Discussing which parts of our experience with Operation Warp Speed can be built into our industry’s long-term future

Carlo de Notaristefani
Lead, Manufacturing & Supply Chain Advisor
Operation Warp Speed

An international operations executive with global technical, operational, and P&L experience, Carlo has deep expertise in designing and operating global supply chains in complex regulatory environments, leading accretive M&A activity and devising and executing value-creating strategies in global markets.

Since May 2020, Carlo has been the lead advisor for Manufacturing and Supply Chain to Operation Warp Speed/Federal Covid Response, the US government initiative to support the acceleration of development and supply of Covid-19 vaccines and therapeutics. He has collaborated with the sponsors, suppliers and CDMOs to ensure the fast scale-up of manufacturing and distribution for the entire US.

In Carlo’s most recent corporate position, he was Executive Vice President of Operations at Teva Pharmaceuticals Inc.  In this role he was responsible for all Manufacturing, Technology and Capital Investments, Supply Chain, Quality and Compliance and Procurement operations, as well as the global API and CMO business. Carlo retired from this position in October 2019

Before joining Teva Pharmaceuticals in 2012, Carlo was the President, Technical Operations and Global Support Functions for Bristol Myers Squibb from 2004 to 2011. At BMS he significantly contributed to their successful transformation to a focused biopharma company.

Carlo received his Doctorate in Chemical Engineering and graduated Summa Cum Laude from the University of Naples in Naples, Italy.